Mark Dearnley, chief executive of Hays (LSE:HAS), received 106,121 shares on the vesting of a Performance Share Plan award and sold 50,002 of them, while Tom Way, chief executive of the UK & Ireland business, sold all 106,743 shares that vested to him.
What was announced
Hays plc (LSE:HAS), the recruitment group, published a notification on 25 September 2026 of transactions by two persons discharging managerial responsibilities (PDMRs). Both relate to awards under the company's Performance Share Plan, which the filing records as granted on 25 September 2025.
For each individual, the notification sets out two separate transactions: an Acquisition of shares at nil cost following the vesting of the award, and a subsequent sale of shares on the London Stock Exchange. The acquisitions are vestings of incentive awards rather than market purchases, and no price was paid for the shares received.
Mark Dearnley, Chief Executive Officer
Mr Dearnley acquired 106,121 ordinary shares at £0.00 on vesting. He then sold 50,002 ordinary shares at £0.634782172 per share.
By calculation, the sale was worth approximately £31,740, and it accounted for about 47% of the shares that vested. Also by calculation, that leaves 56,119 of the vested shares not sold under this notification. The filing does not state Mr Dearnley's total shareholding after the transactions, so it is not possible from this announcement alone to say what his overall interest in the company now is.
Tom Way, Chief Executive Officer, UK & Ireland
Mr Way acquired 106,743 ordinary shares at £0.00 on vesting of his Performance Share Plan award. He sold 106,743 ordinary shares at the same price of £0.634782172 per share, meaning the number sold equalled the number that vested.
By calculation, Mr Way's sale was worth approximately £67,759. As with Mr Dearnley, the notification does not give his resulting total holding.
What is not disclosed, and what to watch
Taken together, and again by calculation, 212,864 shares vested across the two executives and 156,745 were sold, for combined proceeds of roughly £99,500 at the disclosed price. Both sales were recorded at the identical price of £0.634782172; the filing does not say whether they were executed together.
The announcement does not give a reason for either sale. In particular, it does not say whether the shares were sold to cover income tax and National Insurance liabilities arising on vesting, and no such explanation should be assumed. Nor does it describe the performance conditions attached to the awards, the proportion of the original grants that vested, or whether any Holding Period applies to shares retained.
The filing records the grant date as 25 September 2025, one year before the vesting. It does not explain the vesting schedule, and the announcement does not indicate whether these awards were part of a wider grant to other employees.
Further detail on Performance Share Plan outcomes, including the measures used and the vesting level achieved, would normally appear in the directors' remuneration report in the company's annual report. Any additional dealings by these or other PDMRs would be published under the UK Market Abuse Regulation. The notification itself contains no trading information or outlook comment.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...